article thumbnail

Data brief: Prevalence of high total cholesterol 11.3% in US adults from Aug. 2021–Aug. 2023

Medical Xpress - Cardiology

The prevalence of high total cholesterol was 11.3% adults from August 2021 to August 2023, according to a November data brief published by the National Center for Health Statistics.

article thumbnail

Harnessing RNA Interference for Cholesterol Lowering: The Bench?to?Bedside Story of Inclisiran

Journal of the American Heart Association

Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovascular disease. Journal of the American Heart Association, Ahead of Print.

article thumbnail

Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study

Heart BMJ

Methods The performance of the CVD microsimulation model, developed using the Cholesterol Treatment Trialists’ Collaboration (CTTC) and UK Biobank cohort, was assessed among participants ≥70 years old at (re)surveys in UK Biobank and the Whitehall II studies.

article thumbnail

Do Statins Cause Dementia?

Dr. Paddy Barrett

I do apologise for being direct, but this issue is one of the most frequent barriers I encounter to initiating cholesterol-lowering therapy. At the exact same time, cholesterol concentrations are also at their lowest. At the exact same time, cholesterol concentrations are also at their lowest. Let’s break this down.

article thumbnail

APOE4 & Cardiovascular Risk

Dr. Paddy Barrett

Every lipoprotein particle has one APO B protein. ( **Please note the B ) When we measure APO B levels, this is what we are measuring to give an estimate of the number of cholesterol particles and the subsequent risk of cardiovascular disease. APO E is also centrally involved in cholesterol metabolism. 2021 Mar 3;13(583):eaaz4564.

article thumbnail

Lipid lowering with inclisiran: a real-world single-centre experience

Open Heart

Objective The reduction in circulating low-density lipoprotein cholesterol (LDL-c) is the primary aim of lipid-lowering therapies as a method of atherosclerotic cardiovascular disease risk reduction. mmol/L and total cholesterol from 5.7±1.3 Data were collected using electronic healthcare records. mmol/L by 48.6% mmol/L by 33.3%

article thumbnail

Novartis Leqvio’s Case for Broader ASCVD Prevention

CardiacWire

Leqvio has a solid FDA track record so far… It initially gained approval in 2021 for people with ASCVD or heterozygous familial hypercholesterolemia who are already taking statins. Then in 2023 it gained an expanded approval to include primary prevention among statin-taking adults with high LDL-C and high ASCVD risks.